Where are we on a deal?, page-1289

First 1289 Last

Share
Profile

Follow
the buck

405 Posts.

156

29/05/25

11:53

Post #: 79234123
Share

Originally posted by asx11: ↑

great, the Sharewise interview and the AGM both took place before FDA clearance, with the AGM occurring after the Sharewise interview. Therefore, the updated commentary at the AGM takes precedence over the earlier statements.

Since in the AGM commentary he stated that he believed a deal would happen in 2025, and knowing that negotiations can take time, I certainly didn’t expect one by now. "I certainly have not been expecting one by now." Based on how long deals typically take, my own guess would be that it might happen later in 2025, if it does at all. This is supported by my earlier comment about being pleasantly surprised if it occurred before Q2. "I'll be pleasantly suprised if a funding deal happens before Q2 CY2025."

We are still in 2025.

So why did you say, "You state you are not expecting a deal, and I find that strange," when you know I actually said, "I certainly have not been expecting one by now" which you even quoted?

And why are you disregarding the AGM commentary and fixating on your interpretation of the outdated remarks remarks when that may lead to confusion and could be misinterpreted as an instance of PR overpromising or misleading shareholders.

Expand

Not sure we can meet the trial schedule commitments made by PR without funding very early in the peace. Happy to be corrected though

PAR Price at posting: 31.5¢ Sentiment: Hold Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

First 1289 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 33.0¢		Change -0.005(1.49%)		Mkt cap ! $128.5M

Open	High	Low	Value	Volume
33.5¢	34.0¢	32.0¢	$128.6K	392.4K

Buyers (Bids)

No.	Vol.	Price($)
5	131345	32.5¢

Sellers (Offers)

Price($)	Vol.	No.
33.0¢	10	1

View Market Depth

No.	Vol.	Price($)
5	142932	0.325
8	65895	0.320
5	17298	0.315
4	18343	0.310
2	71752	0.305

Price($)	Vol.	No.
0.335	58120	2
0.340	84637	2
0.345	2471	2
0.350	31494	7
0.355	26700	3

Last trade - 12.32pm 27/06/2025 (20 minute delay)

PAR (ASX) Chart

Where are we on a deal?, page-1289

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Where are we on a deal?, page-1289

Top Stories

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News